Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Trial Profile

Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Endostatin (Primary) ; Cisplatin; Docetaxel
  • Indications Nasopharyngeal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Sep 2012 New source identified and integrated (ClinicalTrials.gov record: NCT01689558)
    • 24 Sep 2012 Planned End Date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 15 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top